Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction
Launched by MEDICAL UNIVERSITY OF VIENNA · May 30, 2016
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged greater than 18 years.
- • Written informed consent.
- • Requirement for haemodialysis using a tunneled dialysis catheter.
- Exclusion Criteria:
- • Children aged less than 18 years.
- • Positive blood culture in previous seven days before catheter insertion.
- • Heparin induced thrombocytopenia and any contraindication for anticoagulation (recent or planned surgery, thrombocytopenia \< 70G/l, bleeding disorder).
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Guerkan Sengoelge, MD
Principal Investigator
Medical University of Vienna, Department of Medicine III, Division of Nephrology and Dialysis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials